COMPREHENSIVE SAFETY AND EFFICACY EVALUATION OF IMMUNOTHERAPY COMBINATION APPROACHES VERSUS TYROSINE-KINASE INHIBITOR MONOTHERAPY AS FIRST-LINE TREATMENT OF HEPATOCELLULAR CARCINOMA: A NETWORK AND INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS (AASLD 2026) - Oct 6, 2026 - Abstract #4277; Pres time: Nov 8, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; "Historically, tyrosine-kinase inhibitor (TKI) monotherapies such as sorafenib and lenvatinib served as the primary systemic standard of care...A total of 6,161 patients were included in the analysis, which categorized treatment into five primary strategies: ICPI monotherapy, ICPI plus bevacizumab, dual ICPI (duplet), ICPI plus TKI, and TKI monotherapy as the control group...Among FDA-approved regimens, Nivolumab plus Ipilimumab (NivoIpi) achieved the longest median OS of 24.08 months... ICPI-containing combination therapies are superior to TKI monotherapy for the first-line treatment of advanced HCC, providing marked improvements in survival outcomes. Dual ICPI therapy represents the most balanced approach between efficacy and safety, achieving high survival with the lowest rates of severe toxicity. Among approved options, NivoIpi demonstrated the strongest survival signal, while DurvaTreme offered the highest tolerability, supporting a personalized treatment..."
Monotherapy • Retrospective data • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor
|
|
Maen Abdelrahim1; Abdullah Esmail2; Yazan Hamdaneh2; Zaid Al-Abed2; Ebtesam Al-najjar2; Nour Mustafa2
|